(Z)-4-((R)-2,2-Diethyl-[1,3]dioxolan-4-yl)-3-methyl-but-2-enoic acid methyl ester | 897628-28-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-4-((R)-2,2-Diethyl-[1,3]dioxolan-4-yl)-3-methyl-but-2-enoic acid methyl ester
• CAS: 897628-28-3
• 化学式: C₁₃H₂₂O₄
• 分子量: 242.315
• InChiKey: HWJRAIUFWIROEP-HIJJYWJESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.43
• 重原子数：
  17.0
• 可旋转键数：
  5.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  44.76
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (Z)-4-((R)-2,2-Diethyl-[1,3]dioxolan-4-yl)-3-methyl-but-2-enoic acid methyl ester 在 咪唑 、 Dowex 50W X₈ 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 (R)-6-(tert-Butyl-diphenyl-silanyloxymethyl)-4-methyl-5,6-dihydro-pyran-2-one
  参考文献：
  名称：

  Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agents

  摘要：

  Novel kazusamycin A derivatives were designed in the viewpoint of decrease of reactivity at the alpha,beta-unsaturated delta-lactone moiety against Michael-type addition. Although 25-30 steps were required for the synthesis of each compound, their syntheses were achieved. Cytotoxicity against HPAC cell line was evaluated, and two of them exhibited comparable potency to kazusamycin A. Hepatic toxicity of these designed compounds was much lower than that of kazusamycin A. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.056
• 作为产物：
  描述：

  在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 生成 (Z)-4-((R)-2,2-Diethyl-[1,3]dioxolan-4-yl)-3-methyl-but-2-enoic acid methyl ester
  参考文献：
  名称：

  Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agents

  摘要：

  Novel kazusamycin A derivatives were designed in the viewpoint of decrease of reactivity at the alpha,beta-unsaturated delta-lactone moiety against Michael-type addition. Although 25-30 steps were required for the synthesis of each compound, their syntheses were achieved. Cytotoxicity against HPAC cell line was evaluated, and two of them exhibited comparable potency to kazusamycin A. Hepatic toxicity of these designed compounds was much lower than that of kazusamycin A. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.03.056